Also trades as: AUP.TO (TSX) · $vol 4M
AUPH NASDAQ
Aurinia Pharmaceuticals Inc.
1W: -2.8%
1M: -2.6%
3M: +8.7%
YTD: +1.3%
1Y: +89.9%
3Y: +44.8%
5Y: +37.7%
$15.80
+0.25 (+1.61%)
Weekly Expected Move ±6.0%
$13
$14
$15
$16
$17
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$12.7M
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.0B
52W Range7.285-16.88
Volume775,504
Avg Volume1,177,847
Beta1.45
Dividend—
Analyst Ratings
Company Info
CEOKevin C. Tang
Employees130
SectorHealthcare
IndustryBiotechnology
IPO Date2014-09-03
Websiteauriniapharma.com
4464 Markham Street
Edmonton, BC V8Z 7X8
CA
Edmonton, BC V8Z 7X8
CA
12507084272
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Latest News
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates
Aurinia Pharma GAAP EPS of $0.25 beats by $0.05, revenue of $77.7M beats by $0.72M
Guardian Pharmacy Services (GRDN) Q1 Earnings and Revenues Surpass Estimates
Select Medical (SEM) Lags Q1 Earnings Estimates
ARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock?
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Cole Ryan | 0 | — | 2026-03-23 | |
| Hearne Michael S | 0 | — | 2026-03-23 | |
| Keenan Greg | F-InKind | 8,069 | $14.32 | 2026-03-06 |
| TANG KEVIN | P-Purchase | 184,208 | $14.22 | 2026-03-03 |
| TANG KEVIN | P-Purchase | 115,792 | $14.21 | 2026-03-02 |